

Complete genome sequence of a clinical *Bordetella pertussis* isolate from Brazil

Bruno Gabriel N Andrade¹, Michel F Abanto Marin¹, Diego Duque Cambuy¹,
Erica Lourenço Fonseca^{1/+}, Nadjla Ferreira Souza², Ana Carolina P Vicente¹

¹Laboratório de Genética Molecular de Microorganismos, Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, RJ, Brasil

²Laboratório Central de Saúde Pública Dr Milton Sobral, Recife, PE, Brasil

There has been a resurgence in the number of pertussis cases in Brazil and around the world. Here, the genome of a clinical Bordetella pertussis strain (Bz181) that was recently isolated in Brazil is reported. Analysis of the virulence-associated genes defining the pre- and post-vaccination lineages revealed the presence of the prn2-ptxS1A-fim3B-ptxP3 allelic profile in Bz181, which is characteristic of the current pandemic lineage. A putative metallo-β-lactamase gene presenting all of the conserved zinc-binding motifs that characterise the catalytic site was identified, in addition to a multidrug efflux pump of the RND family that could confer resistance to erythromycin, which is the antibiotic of choice for treating pertussis disease.

Key words: *ptxP3* - pandemic lineage - virulence factors - antigenic variant

The genus *Bordetella* consists of Gram-negative β-proteobacteria, including the three human pathogens *Bordetella pertussis*, *Bordetella parapertussis* and *Bordetella bronchiseptica*, which are considered the classical *Bordetella* species (van der Zee et al. 1996). *B. pertussis*, a fastidious but highly contagious bacterium, is a strict human pathogen and has no known animal or environmental reservoir [for revision, Mattoo and Cherry (2005)].

Whooping cough (pertussis) is a consequence of upper respiratory tract colonisation by *B. pertussis* and is characterised by symptoms such as fever and coughing, which persist for more than a week. During this stage, *B. pertussis* can be isolated and antibiotics are used to control the infection. If the infection persists, a toxæmic stage is achieved, with a characteristic inspiratory gasp (whoop) that is not controlled by antibiotics. Pertussis shows a significant mortality rate in infants and was one of the most frequent and severe disease in this group before the worldwide introduction of an immunisation programme in the 1950s. Although immunisation with a cellular vaccine was effective in the late XX century, this type of vaccine has been replaced by acellular pertussis vaccines in several countries due to its side effects. In Brazil, pertussis is controlled by the Brazilian National Immunisation Program by administering a whole-cell vaccine; however, acellular vaccines have also been available since 2006. In the 1990s, pertussis reemerged even in countries with highly vaccinated populations and it is currently the most prevalent vaccine-prevent-

able disease, representing a public health threat even in developed countries (Hartzell & Blaylock 2014).

The emergence of strains harbouring allelic variants of the antigens used in vaccine development is one of the possible causes of pertussis resurgence. A number of studies have documented the circulation of strains with allelic variants that differ from those of the vaccine strain (van Loo et al. 2002, Kallonen et al. 2011). In most cases, these alleles present single-nucleotide polymorphisms that result in antigenic divergence relative to the antigens present in the vaccine.

In 2003, the first complete genomes of the classical *Bordetella* subspecies were published, revealing the genetic determinants of their distinct phenotypes (Parkhill et al. 2003, Bart et al. 2010). A recent study based on whole-genome analyses evaluated *B. pertussis* strains recovered worldwide, though no Brazilian strain was included. This study indicated the existence of at least two major *B. pertussis* lineages related to the pre and post-vaccination periods (Harvill et al. 2013, Bart et al. 2014). Although there has been a lack of characterisation of strains circulating in Brazil, pertussis has also reemerged in this country. Here, we report the first *B. pertussis* genome sequence of a clinical strain isolated in the northeastern region of Brazil (Bz181), in 2013.

The *B. pertussis* Bz181 strain is deposited in the Collection of Bacteria of the Environment and Health at the Oswaldo Cruz Foundation (Fiocruz), Brazil. Whole-genome sequencing of this strain was performed using a Nextera paired-end library on an Illumina HiSeq 2500 sequencer within the high-throughput platform of the Oswaldo Cruz Institute, Fiocruz. The sequencing generated 10,120,624 reads with an average read length of 87 bp. The paired-end reads were *de novo* assembled using the a5 assembly pipeline, which yielded a database composed of 295 contigs, totalling ~3.82 Mb, with an average G+C content of 67.7%. Gene prediction and annotation were performed with the NCBI Prokaryotic Genome Automatic Annotation Pipeline. An overall

doi: 10.1590/0074-0276140288

Financial support: FAPERJ, CNPq, IOC

+ Corresponding author: ericafon@ioc.fiocruz.br

Received 7 August 2014

Accepted 7 October 2014

cies genome projects revealed the presence of this sequence in all *B. pertussis* genomes. However, in the *B. parapertussis* and *B. bronchiseptica* genomes, several different metallo- β -lactamase-like alleles were identified, including sequences with a nucleotide insertion resulting in a premature stop codon.

Classification of functional subsystems performed using RAST demonstrated the presence of putative genes associated with resistance in Bz181, including the multi-drug resistance-related CmeABC efflux pump from the RND superfamily (membrane fusion protein CmeA, GenBank accession KM668555, inner membrane transporter CmeB, GenBank accession KM668556, outer membrane lipoprotein CmeC, GenBank accession KM668554). Although this efflux pump has never been reported in *Bordetella*, a search performed in GenBank revealed the presence of the *cme* operon in other *Bordetella* genomes. This efflux pump has been reported and characterised in *Campylobacter* and is involved in resistance to clinically important antibiotics used to treat infections caused by this organism, such as fluoroquinolones, erythromycin, tetracycline, rifampin, gentamycin and some β -lactams (Lin et al. 2002). Macrolides, especially erythromycin, have been the drug of choice for the treatment and post-exposure prophylaxis of pertussis (Langley et al. 2004). Therefore, the presence of a putative CmeABC efflux pump in Bz181, which could evoke erythromycin resistance, is of concern and further experimental assays to determine its role and functionality must be performed. However, the mutations responsible for the emergence of fluoroquinolone resistance were not detected in the *gyrA* and *parC* sequences of Bz181.

The findings presented in this report provide relevant genomic information concerning the current epidemiological scenario of pertussis in Brazil, where the major pertussis immunisation policy is based on a whole-cell vaccine. The results of this work will contribute to a better understanding of *B. pertussis* evolution.

ACKNOWLEDGEMENTS

To PDTIS-Fiocruz and to Platform, for high-throughput sequencing of IOC-Fiocruz for use of their facilities.

REFERENCES

- Aricó B, Miller JF, Roy C, Stibitz S, Monack D, Falkow S, Gross R, Rappuoli R 1989. Sequences required for expression of *Bordetella pertussis* virulence factors share homology with prokaryotic signal transduction proteins. *Proc Natl Acad Sci USA* 86: 6671-6675.
- Bart MJ, Harris SR, Advani A, Arakawa Y, Bottero D, Bouchez V, Cassidy PK, Chiang CS, Dalby T, Fry NK, Gaillard ME, van Gent M, Guiso N, Hallander HO, Harvill ET, He Q, van der Heide HG, Heuvelman K, Hozbor DF, Kamachi K, Karataev GI, Lan R, Lutyńska A, Maharjan RP, Mertsola J, Miyamura T, Octavia S, Preston A, Quail MA, Sintchenko V, Stefanelli P, Tondella ML, Tsang RS, Xu Y, Yao SM, Zhang S, Parkhill J, Mooi FR 2014. Global population structure and evolution of *Bordetella pertussis* and their relationship with vaccination. *MBio* 5: e01074.
- Bart MJ, van Gent M, van der Heide HG, Boekhorst J, Hermans P, Parkhill J, Mooi FR 2010. Comparative genomics of prevaccination and modern *Bordetella pertussis* strains. *BMC Genomics* 11: 627.
- Garau G, García-Sáez I, Bebrone C, Anne C, Mercuri P, Galleni M, Frère JM, Dideberg O 2004. Update of the standard numbering scheme for class B β -lactamases. *Antimicrob Agents Chemother* 48: 2347-2349.
- Hartzell JD, Blaylock JM 2014. Whooping cough in 2014 and beyond: an update and review. *Chest* 146: 205-214.
- Harvill ET, Goodfield LL, Ivanov Y, Meyer JA, Newth C, Cassidy P, Tondella ML, Liao P, Zimmerman J, Meert K, Wessel D, Berger J, Dean JM, Holubkov R, Burr J, Liu T, Brinkac L, Kim M, Losada L 2013. Genome sequences of 28 *Bordetella pertussis* US outbreak strains dating from 2010 to 2012. *Genome Announc* 1: e01075-13.
- Kallonen T, Gröndahl-Yli-Hannuksela K, Elomaa A, Lutynska A, Fry NK, Mertsola J, He Q 2011. Differences in the genomic content of *Bordetella pertussis* isolates before and after introduction of pertussis vaccines in four European countries. *Infect Genet Evol* 11: 2034-2042.
- Langley JM, Halperin SA, Boucher FD, Smith B, Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) 2004. Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. *Pediatrics* 114: e96-e101.
- Lin J, Michel LO, Zhang Q 2002. CmeABC functions as a multi-drug efflux system in *Campylobacter jejuni*. *Antimicrob Agents Chemother* 46: 2124-2131.
- Mattoo S, Cherry JD 2005. Molecular pathogenesis, epidemiology and clinical manifestations of respiratory infections due to *Bordetella pertussis* and other *Bordetella* subspecies. *Clin Microbiol Rev* 18: 326-382.
- Parkhill J, Sebahia M, Preston A, Murphy LD, Thomson N, Harris DE, Holden MT, Churcher CM, Bentley SD, Mungall KL, Cerdeño-Tárraga AM, Temple L, James K, Harris B, Quail MA, Achtman M, Atkin R, Baker S, Basham D, Bason N, Cherevach I, Chillingworth T, Collins M, Cronin A, Davis P, Doggett J, Feltwell T, Goble A, Hamlin N, Hauser H, Holroyd S, Jagels K, Leather S, Moule S, Norberczak H, O'Neil S, Ormond D, Price C, Rabinowitsch E, Rutter S, Sanders M, Saunders D, Seeger K, Sharp S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Unwin L, Whitehead S, Barrell BG, Maskell DJ 2003. Comparative analysis of the genome sequences of *Bordetella pertussis*, *Bordetella parapertussis* and *Bordetella bronchiseptica*. *Nat Genet* 35: 32-40.
- van der Zee A, Groenendijk H, Peeters M, Mooi FR 1996. The differentiation of *Bordetella parapertussis* and *Bordetella bronchiseptica* from humans and animals as determined by DNA polymorphism mediated by two different insertion sequence elements suggests their phylogenetic relationship. *Int J Syst Bacteriol* 46: 640-647.
- van Loo IH, Heuvelman KJ, King AJ, Mooi FR 2002. Multilocus sequence typing of *Bordetella pertussis* based on surface protein genes. *J Clin Microbiol* 40: 1994-2001.